Jeffrey Conn

Phase I clinical trial of drug was successfully completed at the Warren Center for Neuroscience Drug Discovery, with promise to treat Alzheimer’s and other neurodegenerative diseases. The compound, named VU319, is the first Vanderbilt end-to-end drug discovery effort related to memory loss, starting from the earliest basic science research through human clinical trials. Read More

Stressful experiences can lead to adaptive or detrimental behaviors. Understanding how stress can affect our brains can help understand basic brain function and is also essential to discerning causes and treatments for some diseases. A group of researchers led by Jeffrey Conn, professor of pharmacology at… Read More